Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. The patient has signed an Informed Consent Form in accordance with GCP and local legislative requirements prior to participation in the trial, i.e., prior to pre-trial washout of any restricted medications.~2. The patient has a clinical diagnosis of chronic obstructive pulmonary disease (COPD).~3. The patient has relatively stable, moderate to severe airway obstruction.~4. The patient has a pre-bronchodilator forced expiratory volume in the first second (FEV1) less than or equal to 65% of predicted normal determined at Visit 1 using the following predicted equations (R94-1408):~   1. Males Forced expiratory volume in the first second (FEV1) predicted \[Litres (L)\] = 4.30 x Height \[metres\] minus 0.029 x Age \[years\] minus 2.49~  2. Females Forced expiratory volume in the first second (FEV1) predicted \[Litres (L)\] = 3.95 x Height \[metres\] minus 0.025 x Age \[years\] minus 2.60 and a Thoracic Gas Volume (Functional residual volume) ((TGV)(FRC)) bigger than 120% predicted normal at visit 1 (or historical data not older than 6 month)~  3. Males Thoracic Gas Volume (Functional residual volume) ((TGV(FRC)) pred. \[Litres (L)\] = 2.34 x Height \[metres\] + 0.009 x Age \[years\] minus 1.09~  4. Females Thoracic Gas Volume (Functional residual volume) ((TGV(FRC)) pred. \[Litres (L)\] = 2.24 x Height \[metres\] + 0.001 x Age \[years\] minus 1.00~5. The patient is at least 40 years and less than or equal to 75 years old.~6. The patient has a cigarette smoking history of at least 10 pack-years. A pack-year is defined as the equivalent of smoking one pack of cigarettes per day for a year.~7. The patient is able to perform all specified procedures and able to maintain all necessary records during the study period as required in the protocol.~8. The patient is able to inhale the trial medication from the HandiHaler device.~9. The patient is able to inhale the trial medication from the Diskus/Accuhaler device.~Exclusion Criteria:~1. a significant disease other than chronic obstructive pulmonary disease (COPD). (review contraindications for exercise testing),~2. a recent history of myocardial infarction within one year.~3. a recent history of heart failure, pulmonary oedema, or patients with cardiac arrhythmia or any contraindication to exercise described in the CTProtocol within the last 3.~4. daytime supplemental oxygen.~5. a diagnosis of known active tuberculosis.~6. a history of cancer within the last 5 years.~7. a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis.~8. thoracotomy with pulmonary resection.~9. an upper respiratory tract infection or an exacerbation of chronic obstructive pulmonary disease (COPD)~10. a known hypersensitivity to anticholinergic drug, ß-adrenergic or corticosteroids, lactose or any other component of the inhalation capsule delivery system.~11. a known symptomatic prostatic hypertrophy or bladder neck obstruction.~12. a known moderate or severe renal insufficiency.~13. a known narrow-angle glaucoma.~14. a known untreated hypokalemia.~15. a known untreated thyrotoxicosis.~16. a history of asthma, allergic rhinitis or atopy, or a total blood eosinophil count larger than 600/mm3.~17. treatment with cromolyn sodium or nedocromil sodium~18. treatment with antihistamines or antileukotrienes.~19. treatment with tiotropium for 1 month before Visit 1.~20. treatment with oral corticosteroid medication.~21. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception~22. a history of or active alcohol or drug abuse.~23. an investigational drug within 1 month or 10 half lives~24. a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea.~25. participation in a rehabilitation program for chronic obstructive pulmonary disease (COPD).~26. treatment with monoamine oxidase inhibitors inhibitors or tricyclic antidepressants.~27. participation in another study.~28. more than eight puffs of salbutamol/day during the run-in period

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).